$3.70
-0.11[-2.89%]
At close: Apr 24
$3.70
0[0.00%]
PreMarket: 6:21PM EDT
Akoya Biosciences
(NASDAQ:AKYA)Akoya Biosciences Stock (NASDAQ:AKYA), Analyst Ratings, Price Targets, Predictions
Akoya Biosciences Inc has a consensus price target of $12.77, established from looking at the 27 latest analyst ratings. The last 3 analyst ratings were released from JP Morgan, UBS, and Canaccord Genuity on March 6, 2024, March 5, 2024, and March 5, 2024. With an average price target of $9.17 between JP Morgan, UBS, and Canaccord Genuity, there's an implied 147.75% upside for Akoya Biosciences Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
UBS
Canaccord Genuity
Guggenheim
Piper Sandler
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Akoya Biosciences
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/06/2024 | AKYA | Buy Now | Akoya Biosciences | $3.70 | 170.27% | JP Morgan | Tycho Peterson | $12 → $10 | Maintains | Overweight | Get Alert |
| 03/05/2024 | AKYA | Buy Now | Akoya Biosciences | $3.70 | 102.7% | UBS | John Sourbeer | $7 → $7.5 | Maintains | Buy | Get Alert |
| 03/05/2024 | AKYA | Buy Now | Akoya Biosciences | $3.70 | 170.27% | Canaccord Genuity | Kyle Mikson | → $10 | Reiterates | Buy → Buy | Get Alert |
| 12/14/2023 | AKYA | Buy Now | Akoya Biosciences | $3.70 | — | Guggenheim | Subbu Nambi | — | Initiates | → Neutral | Get Alert |
| 11/13/2023 | AKYA | Buy Now | Akoya Biosciences | $3.70 | 116.22% | Piper Sandler | David Westenberg | $11 → $8 | Maintains | Overweight | Get Alert |
| 11/13/2023 | AKYA | Buy Now | Akoya Biosciences | $3.70 | 143.24% | Stephens & Co. | Mason Carrico | $14 → $9 | Maintains | Overweight | Get Alert |
| 10/24/2023 | AKYA | Buy Now | Akoya Biosciences | $3.70 | 116.22% | Morgan Stanley | Tejas Savant | $15 → $8 | Maintains | Overweight | Get Alert |
| 10/16/2023 | AKYA | Buy Now | Akoya Biosciences | $3.70 | 197.3% | Piper Sandler | David Westenberg | $14 → $11 | Maintains | Overweight | Get Alert |
| 10/12/2023 | AKYA | Buy Now | Akoya Biosciences | $3.70 | 89.19% | UBS | John Sourbeer | $12 → $7 | Maintains | Buy | Get Alert |
| 08/08/2023 | AKYA | Buy Now | Akoya Biosciences | $3.70 | 305.41% | Morgan Stanley | Tejas Savant | $16 → $15 | Maintains | Overweight | Get Alert |
| 08/08/2023 | AKYA | Buy Now | Akoya Biosciences | $3.70 | 332.43% | Stephens & Co. | Mason Carrico | → $16 | Reiterates | Overweight → Overweight | Get Alert |
| 05/10/2023 | AKYA | Buy Now | Akoya Biosciences | $3.70 | 332.43% | Morgan Stanley | Tejas Savant | $17 → $16 | Maintains | Overweight | Get Alert |
| 03/21/2023 | AKYA | Buy Now | Akoya Biosciences | $3.70 | 332.43% | Stephens & Co. | Mason Carrico | → $16 | Reiterates | → Overweight | Get Alert |
| 03/08/2023 | AKYA | Buy Now | Akoya Biosciences | $3.70 | 359.46% | Morgan Stanley | Tejas Savant | $18 → $17 | Maintains | Overweight | Get Alert |
| 11/03/2022 | AKYA | Buy Now | Akoya Biosciences | $3.70 | 413.51% | Capital One | Timothy Chiang | → $19 | Initiates | → Overweight | Get Alert |
| 10/06/2022 | AKYA | Buy Now | Akoya Biosciences | $3.70 | 332.43% | Stephens & Co. | Mason Carrico | → $16 | Initiates | → Overweight | Get Alert |
| 08/17/2022 | AKYA | Buy Now | Akoya Biosciences | $3.70 | 359.46% | Piper Sandler | David Westenberg | $14 → $17 | Maintains | Overweight | Get Alert |
| 06/22/2022 | AKYA | Buy Now | Akoya Biosciences | $3.70 | 332.43% | BTIG | Mark Massaro | → $16 | Initiates | → Buy | Get Alert |
| 05/16/2022 | AKYA | Buy Now | Akoya Biosciences | $3.70 | 278.38% | Piper Sandler | David Westenberg | $18 → $14 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Akoya Biosciences (AKYA)?
The latest price target for Akoya Biosciences (NASDAQ: AKYA) was reported by JP Morgan on March 6, 2024. The analyst firm set a price target for $10.00 expecting AKYA to rise to within 12 months (a possible 170.27% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Akoya Biosciences (AKYA)?
The latest analyst rating for Akoya Biosciences (NASDAQ: AKYA) was provided by JP Morgan, and Akoya Biosciences maintained their overweight rating.
When was the last upgrade for Akoya Biosciences (AKYA)?
There is no last upgrade for Akoya Biosciences.
When was the last downgrade for Akoya Biosciences (AKYA)?
There is no last downgrade for Akoya Biosciences.
When is the next analyst rating going to be posted or updated for Akoya Biosciences (AKYA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Akoya Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Akoya Biosciences was filed on March 6, 2024 so you should expect the next rating to be made available sometime around March 6, 2025.
Is the Analyst Rating Akoya Biosciences (AKYA) correct?
While ratings are subjective and will change, the latest Akoya Biosciences (AKYA) rating was a maintained with a price target of $12.00 to $10.00. The current price Akoya Biosciences (AKYA) is trading at is $3.70, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.